Optimum Patient Care Australia

Optimum Patient Care Australia is a The Royal Australian College of General Practitioners (RACGP) Accredited Education Provider, and is renowned for it’s clinical reviews, research initiatives and database. Learn more about us here: https://bit.ly/3Rutrd6 #OPCA #OptimumPatientCare #RACGP #PrimaryCare

OPRI's latest publication, 'Preserved Ratio Impaired Spirometry in US Primary Care Patients Diagnosed with Chronic Obstructive Pulmonary Disease', examines data sourced from the APEX COPD registry revealing that 1 in 4 patients with COPD in primary care presents with Preserved Ratio Impaired Spirometry (PRISm)   Read the full press release: https://lnkd.in/gcUN-P5E   Read the full article here: https://lnkd.in/g_thizWU   #ResearchInRealLife #Research #COPD #PrimaryCare

Live at ISPOR Europe now 📢 Heath Heatley is presenting our research on “Do asthma patients prescribed a GLP1 have improved asthma and weight loss outcomes?”. If you missed it, come see poster board number 1026.  🫁 #ispor #isporeurope #asthma #copd #opcrd #research

Live at ISPOR now, 📢 Heath Heatley is presenting our research on “Excess SABA prescribing in respiratory patients and social deprivation in general practice: a study of 4 million patients”. If you missed it, come see poster board number 1024.  🫁

🌍 Did you know that chronic obstructive pulmonary disease (COPD) is one of the leading causes of death worldwide? Join us at Medscape LIVE! Webinar hosted by Medscape Education where Professor David Price and expert faculty will dive into the critical, unmet needs in COPD diagnosis, "A Wakeup Call to Early COPD Diagnosis: Why it Matters and How to Achieve it". Topics will cover: ◾ The importance of early diagnosis ◾ Strategies to enhance early detection ◾ Risk factors for COPD development ◾ The role of spirometry and other screening tools to identify at-risk populations 📅 Date: 28 November 2024 ⏰ Time: 15:00 CET Don’t miss this chance to gain practical insights and interact with leading experts in the field! Register here 👉https://lnkd.in/gFuX3djr #COPD #SevereAsthma #MedscapeLive #webinar #HealthcareInnovation #COPDWebinar #RespiratoryHealth #COPDAwareness

The EVEREST study published in the Journal of Asthma and Allergy, “Disease Burden and Access to Biologic Therapy in Patients with Severe Asthma, 2017–2022: An Analysis of the International Severe Asthma Registry”, has shed light on the significant global disease burden faced by patients suffering from severe asthma, including those without access to biologic therapies, those who were eligible but did not receive these treatments, and T2-targeted biologic recipients. The findings underscore the urgent need for improved healthcare resource utilization, increased access to biologics, and ongoing research on new treatment options to address the unmet needs of patients with severe asthma. Read the full press release: https://lnkd.in/g93bnptj Read the full article here: https://lnkd.in/gXYdYMS3 #ResearchInRealLife #SevereAsthma #Asthma #Research

We're #hiring a new Graduate Data Analyst in Brisbane, Queensland. Apply today or share this post with your network.

We are pleased to present our new Article Collection entitled “Real-World Asthma Management: A Spotlight on Pragmatic and Observational Research.” This Collection is now live in Pragmatic and Observational Research, a gold open-access journal published by Taylor & Francis. The deadline to submit is March 30th, 2025. Interested in submitting to the Collection? Find out more by reaching out to the Commissioning Editor, Haoyang Yi, at haoyang.yi@taylorandfrancis.com. https://lnkd.in/g4mG5syR

The International Severe Asthma Registry (ISAR)’s new study, “Exploring definitions and predictors of response to biologics for severe asthma”, published in The Journal of Allergy and Clinical Immunology: In Practice (JACI: In Practice), explores the effectiveness of biologic treatments in adults with severe asthma. Given the variability in asthma response based on differing definitions, this study focuses on identifying predictors of response and examining residual symptoms post-treatment. Read the full press release: https://lnkd.in/gJRe-SFy Read the full article here: https://lnkd.in/gGxKa37g #ResearchInRealLife #SevereAsthma #Asthma #Research

We are excited to share groundbreaking findings on remission as a therapeutic target in “Exploring definitions and predictors of severe asthma clinical remission post-biologic in adults (FULL BEAM remission)’, recently published in the American Journal of Respiratory and Critical Care Medicine. This International Severe Asthma Registry (ISAR) study, which spanned 23 countries and followed the asthma journeys of over 3,000 real-life patients with severe asthma, reported the prevalence of remission after starting biologic therapy and identified factors associated with achieving it. Read the full press release: https://lnkd.in/gEa-5YJt Read the full article here: https://lnkd.in/gg9GTfTU #ResearchInRealLife #SevereAsthma #Asthma #Research